candesartan has been researched along with Leanness in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 9.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 5.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pocock, SJ | 1 |
| McMurray, JJ | 1 |
| Dobson, J | 1 |
| Yusuf, S | 1 |
| Granger, CB | 1 |
| Michelson, EL | 1 |
| Ostergren, J | 1 |
| Pfeffer, MA | 1 |
| Solomon, SD | 1 |
| Anker, SD | 1 |
| Swedberg, KB | 1 |
| Hu, J | 1 |
| Tiwari, S | 1 |
| Riazi, S | 1 |
| Hu, X | 1 |
| Wang, X | 1 |
| Ecelbarger, CM | 1 |
1 trial available for candesartan and Leanness
| Article | Year |
|---|---|
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2008 |
1 other study available for candesartan and Leanness
| Article | Year |
|---|---|
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarker | 2009 |